Mast Therapeutics (NASDAQ: SVRA) is one of 293 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Mast Therapeutics to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of current ratings for Mast Therapeutics and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mast Therapeutics 0 0 4 0 3.00
Mast Therapeutics Competitors 717 3149 11750 262 2.73

Mast Therapeutics currently has a consensus price target of $24.50, suggesting a potential upside of 159.26%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 29.02%. Given Mast Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Mast Therapeutics is more favorable than its peers.

Earnings and Valuation

This table compares Mast Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Mast Therapeutics $400,000.00 -$16.56 million -1.41
Mast Therapeutics Competitors $473.33 million $171.79 million -7.09

Mast Therapeutics’ peers have higher revenue and earnings than Mast Therapeutics. Mast Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Mast Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mast Therapeutics N/A -121.52% -65.80%
Mast Therapeutics Competitors -5,564.68% -392.10% -42.63%

Volatility & Risk

Mast Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, Mast Therapeutics’ peers have a beta of 6.61, indicating that their average share price is 561% more volatile than the S&P 500.

Insider & Institutional Ownership

16.5% of Mast Therapeutics shares are owned by institutional investors. Comparatively, 51.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 6.9% of Mast Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Mast Therapeutics peers beat Mast Therapeutics on 7 of the 12 factors compared.

About Mast Therapeutics

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with's FREE daily email newsletter.